2900008C10Rik Activators
Chemical activators of BCL6 interacting corepressor work by modulating the acetylation status of histones, which in turn affects the chromatin structure and the ability of the corepressor to bind to its target genes. Histone deacetylases (HDACs) are enzymes that remove acetyl groups from histones, leading to a closed chromatin conformation and reduced gene expression. The compounds listed, such as Trichostatin A, Vorinostat, and Valproic Acid, are HDAC inhibitors, which means they prevent these enzymes from removing acetyl groups from histones. As a result, histones remain acetylated, which is associated with a more open chromatin structure. This open state can facilitate the recruitment of BCL6 interacting corepressor, enhancing its ability to repress gene transcription. The increased acetylation levels, maintained by HDAC inhibitors like Romidepsin, Entinostat, and Panobinostat, promote the activation of BCL6 interacting corepressor by improving its association with chromatin, thereby exerting its gene-silencing effects more effectively.
Furthering this mechanism, chemicals like Belinostat, Mocetinostat, and Givinostat contribute to the elevation of histone acetylation. This biochemical change can activate BCL6 interacting corepressor, which relies on a specific chromatin context to effectively bind and repress gene expression. Similarly, Chidamide, Pracinostat, and Tacedinaline also inhibit HDAC activity, leading to an increase in histone acetylation. The heightened acetylation can serve as a signal for the activation of BCL6 interacting corepressor, allowing it to bind more readily to chromatin. The consistent theme among these chemicals is their capacity to maintain a chromatin environment that is conducive to the activation of BCL6 interacting corepressor, thereby facilitating its role in gene repression. By doing so, these HDAC inhibitors play a crucial role in enabling the BCL6 interacting corepressor to exert its function within the cell.
SEE ALSO...
Items 1 to 10 of 12 total
Display:
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
Trichostatin A | 58880-19-6 | sc-3511 sc-3511A sc-3511B sc-3511C sc-3511D | 1 mg 5 mg 10 mg 25 mg 50 mg | $152.00 $479.00 $632.00 $1223.00 $2132.00 | 33 | |
Trichostatin A inhibits histone deacetylases (HDACs), leading to increased acetylation of histones. This can create a more open chromatin structure that facilitates the recruitment of BCL6 interacting corepressor to its target genes, thereby enhancing its repression activity. | ||||||
Suberoylanilide Hydroxamic Acid | 149647-78-9 | sc-220139 sc-220139A | 100 mg 500 mg | $133.00 $275.00 | 37 | |
Vorinostat, also known as SAHA, is an HDAC inhibitor that can increase the acetylation levels of histones. Higher levels of histone acetylation can promote the binding of BCL6 interacting corepressor to chromatin, activating its repressive function on gene expression. | ||||||
Valproic Acid | 99-66-1 | sc-213144 | 10 g | $87.00 | 9 | |
Valproic Acid acts as an HDAC inhibitor and by elevating histone acetylation, it can potentiate the chromatin association and activation of BCL6 interacting corepressor in the suppression of gene transcription. | ||||||
Romidepsin | 128517-07-7 | sc-364603 sc-364603A | 1 mg 5 mg | $218.00 $634.00 | 1 | |
Romidepsin, a potent HDAC inhibitor, can enhance histone acetylation and thereby facilitate the chromatin binding and activation of BCL6 interacting corepressor in gene repression processes. | ||||||
MS-275 | 209783-80-2 | sc-279455 sc-279455A sc-279455B | 1 mg 5 mg 25 mg | $24.00 $90.00 $212.00 | 24 | |
Entinostat is an HDAC inhibitor that can lead to increased acetylation of histones, which may enable the recruitment and functional activation of BCL6 interacting corepressor at specific genomic loci. | ||||||
Panobinostat | 404950-80-7 | sc-208148 | 10 mg | $200.00 | 9 | |
Panobinostat inhibits HDAC activity, raising histone acetylation levels, which can activate BCL6 interacting corepressor by improving its association with chromatin to exert its repressive effects on gene expression. | ||||||
Belinostat | 414864-00-9 | sc-269851 sc-269851A | 10 mg 100 mg | $156.00 $572.00 | ||
Belinostat is an HDAC inhibitor that can enhance histone acetylation, promoting the activation of BCL6 interacting corepressor by facilitating its binding to epigenetically modified chromatin. | ||||||
Mocetinostat | 726169-73-9 | sc-364539 sc-364539B sc-364539A | 5 mg 10 mg 50 mg | $214.00 $247.00 $1463.00 | 2 | |
Mocetinostat is an HDAC inhibitor that can augment histone acetylation and activate BCL6 interacting corepressor by improving its recruitment to and interaction with chromatin. | ||||||
ITF2357 | 732302-99-7 | sc-364513 sc-364513A | 5 mg 50 mg | $340.00 $1950.00 | ||
Givinostat, an HDAC inhibitor, can increase histone acetylation levels, potentially activating BCL6 interacting corepressor by enhancing its chromatin binding and gene-silencing activity. | ||||||
Chidamide | 743420-02-2 | sc-364462 sc-364462A sc-364462B | 1 mg 5 mg 25 mg | $62.00 $250.00 $1196.00 | ||
Chidamide is an HDAC inhibitor that can lead to elevated histone acetylation, which may activate BCL6 interacting corepressor function by promoting its association with chromatin. | ||||||